Cardiopulmonary bypass reduces pulmonary surfactant activity in infants  by Griese, M. et al.
lung vascular system. This may be particularly detri-
mental in infants because of their higher capillary sur-
face per unit of lung volume.6,7 Damage to the lung cap-
illary endothelium results in interstitial edema, and
damage to the alveolar epithelial cells results in alveo-
lar flooding and edema.5
The edema fluid might directly inactivate the surface-
active properties of pulmonary surfactant, which are of
critical importance to keep the terminal air spaces
patent during respiration and to prevent alveoli from
filling with fluid.8,9 Normal intra-alveolar surfactant
metabolism with conversion of the surface-active large-
aggregate forms into small aggregates may also become
abnormal.10 Last, with precipitating lung injury, dam-
age to the alveolar type II epithelial cells results in alter-
ations of surfactant synthesis, secretion, and composi-
tion.10 All these secondary surfactant abnormalities
have been described in acute respiratory distress syn-
drome of various causes. The functional relevance of
surfactant abnormalities in acute respiratory distress
syndrome is suggested by successful treatment with
exogenous natural surfactant.10-13
Thus the goal of this study was to better define poten-
tial indications for surfactant therapy in a group of
C ardiopulmonary bypass (CPB) surgery induces anacute lung injury.1 Because the severity of the injury
is proportional to the duration of CPB, infants less than
1 year of age who often have complex cardiac anom-
alies represent a group at a higher risk.2 The lung injury
is mainly initiated by shear forces and from contact of
venous blood with the nonphysiologic surfaces of the
CPB circuit, resulting in activated platelets that release
mediators and in activation of the complement and the
kallikrein-kinin systems.3-5 Very early on, polymor-
phonuclear granulocytes are activated, and up to 50% of
the peripheral leukocytes may be sequestered into the
Objective: Infants younger than 1 year of age undergoing cardiopul-
monary bypass surgery often have severe lung injury necessitating
increased postoperative respiratory mechanical support. Inasmuch as
the mechanisms may involve an impairment of the pulmonary surfac-
tant system, our aim was to determine whether changes of surfactant
occur in such infants. Methods: From the day of the operation to day 7
after the operation, serial tracheobronchial small-volume lavages of 19
infants (aged 166 ± 29 days) were fractionated into a small and a large
surfactant aggregate fraction and compared with those of 13 infants
without lung disease (aged 203 ± 33 days). Results: After cardiac opera-
tions with cardiopulmonary bypass surgery, total protein in lavages was
increased 3-fold to 4-fold and decreased linearly with time. Surfactant
protein A was increased on day 1 and day 2 and then decreased, where-
as surfactant protein B and total phospholipids were increased on day 1.
The ratio of phospholipids in small and large surfactant fractions was
unchanged, but the surface activity of the large-aggregate surfactant
was impaired on days 1 to 3. Conclusions: Lung injury in infants after
cardiopulmonary bypass surgery involves significant biochemical and
functional disturbances of the pulmonary surfactant system. Inasmuch
as substitution with natural surfactant might correct these deficiencies,
the potential of this approach to reduce postoperative morbidity needs
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CARDIOPULMONARY BYPASS REDUCES PULMONARY SURFACTANT ACTIVITY IN INFANTS
infants who were at risk for severe lung injury after
CPB. We have characterized the biochemical and func-
tional state of their pulmonary surfactant, obtained
from serial small-volume lavages. 
Patients and methods
Control infants. We studied 13 infants (8 male) healthy
with respect to cardiopulmonary disease (aged 203 ± 33 days,
range 8-391 days). None had a history of chronic respiratory
symptoms or recent upper or lower respiratory tract infec-
tions. All these infants were undergoing elective nuclear
magnetic resonance imaging for diagnosis of conditions such
as hydrocephalus (n = 5), hepatoblastoma (n = 2), ocular
abnormalities (n = 2), battered child syndrome (n = 1), neu-
roblastoma (n = 1), developmental retardation (n = 1), and
spinal abnormalities (n = 1). Small-volume lavage was per-
formed by the blind suctioning technique described below in
detail during general anesthesia (N2O, oxygen, halothane 1%-
5%) and tracheal intubation. The study was approved by our
institutional review board and informed consent was obtained
from the parents before the study.
Infants with CPB. Small-volume lavages from 19 consec-
utive infants with congenital heart disease who underwent
cardiac operations with CPB at the Department of Cardiac
Surgery, Klinikum Grosshadern, University of Munich, were
prospectively collected. Mean age of the infants at operation
was 166 ± 29 days (range 2-378 days) and details of the
infants are given in Table I. For CPB the bypass circuit was
primed with 500 mL of red blood cells and balanced elec-
trolyte solution. After administration of heparin (activated
clotting time about 500 seconds), the right atrium–to–aorta
CPB was initiated. The patients were cooled to 28°C-18°C
during CPB and the lungs were not ventilated. After rewarm-
ing, ventilation was recommenced with an inspired oxygen
fraction (FIO2) of 1.0 and circulation was reestablished. Once
in clinically stable condition, the infants were transferred to
the intensive care unit, and intermittent positive-pressure ven-
tilation was continued. The oxygenation index (OI) was cal-
culated as follows: OI = (Mean airway pressure · Arterial
PO2)/FIO2. Mean airway pressure was derived from this for-
mula: (Ventilatory rate · Inspiratory time/60) · [(Peak inspi-
ratory pressure – Positive end-expiratory pressure) + Positive
end-expiratory pressure], as used earlier.14 The study was
approved by our institutional review board and informed con-
sent from the parents was obtained before the study.
Small-volume lavage procedure and preparation of
lavage fractions. For small-volume lavage, an open-ended
suctioning catheter was inserted blindly through the endotra-
cheal tube and wedged in a distal airway. Then 0.9% saline
solution was instilled at an amount of 1 mL/kg body weight
and withdrawn by gentle suctioning. After filtration through
gauze and centrifugation at 200g for 10 minutes to remove
the cells and debris, the supernatant was stored at –70°C. The
cell-free supernatant was fractionated by differential centrifu-
gation at 40,000g, 4°C for 30 minutes, into a fraction that
contained the small surfactant aggregates, which have less
surface activity, and the more surface-active fraction contain-
ing the large surfactant aggregates.15-17
Phospholipid analysis. As described before,17 aliquots of
the samples were lipid extracted and the phospholipid content
was determined from the content of inorganic phosphate.
After separation of phospholipids by high-performance thin-
layer chromatography, the distribution of phospholipid class-
es was assessed from the phosphorus content of the individ-
ual spots, which were identified by authentic standards.
Phospholipid data are expressed as milligrams of phosphate
measured. Inasmuch as 4% of the phospholipid mass is phos-
phate, the amount of phospholipids in milligrams can be cal-
culated by being multiplied by 25. All measurements were
done in duplicate.
ELISA (solid-phase enzyme-linked immunosorbent
assay) for surfactant protein A and surfactant protein B.
These assays were performed as described previously in
detail.18 The samples were assessed in duplicate.
Surface tension. The surface tension modifying properties
of the specimens were evaluated in a pulsating bubble surfac-
tometer (Electronetics, Amherst, NY). Before measurement,
the samples were resuspended at a phospholipid concentra-
tion of 1 mg/mL in 140 mmol/L NaCl, 10 mmol/L HEPES,
0.5 mmol/L ethylenediaminetetraacetic acid, and 3 mmol/L
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Table I. Clinical characteristics of the patients
Total time Removal of 
Patient on bypass endotracheal 
(age [d], sex) Diagnosis (min) tube (d)
1 (300, F) TOF 214 14
2 (17, F) ASD 132 9
3 (34, F) TAPVC 94 3
4 (6, M) Ivemark syndrome 139 1†
with complex 
cardiac anomaly
5 (152, M) CAVSD 132 3
6 (362, M) CAVSD 138 7
7 (184, M) CAVSD 149 4
8 (328, F) CAVSD 204 23
9 (298, M) VSD 73 1
10 (232, M) VSD 68 1
11 (189, F) VSD, ASD 132 3
12 (184, M) VSD, ASD 90 3
13 (141, F) VSD 140 16
14 (13, F) TAC, ASD 246 13†
15 (168, F) TAC 172 19‡
16 (148, M) TGA, LVOTO, VSD 221 7
17 (26, M) TGA, PDA, VSD, 225 14
ASD
18 (2, F) TGA, PDA, ASD 228 17
19 (378, M) DIRV 113 5
Patients 8 and 14 had a severe nosocomial infection and were not included in
the final analysis of the surfactant status. ASD, Atrial septal defect; CAVSD,
complete atrioventricular septal defect; DIRV, double-inlet right ventricle;
LVOTO, left ventricular outflow tract obstruction; VSD, ventricular septal
defect; PDA, persistent ductus arteriosus; TAC, truncus arteriosus communis;
TAPVR, total anomalous pulmonary venous return; TGA, transposition of the
great arteries; TOF, tetralogy of Fallot.
†Died.
‡Transferred to another hospital receiving ventilatory support.
CaCl2, pH 6.9, at 37˚C. Adsorption ( g ads) was defined as the
surface tension obtained 10 seconds after formation of the
bubble. Minimum surface tension (g
min) was the surface ten-
sion in the equilibrium after 3 minutes of pulsations (20
cycles/min; minimum 0.40 mm and maximum 0.55 mm
radius), read at a minimum radius of the bubble by an auto-
mated computer program.18
Inhibition of surfactant function. To determine the
inhibitory potential of surfactant-associated lavage con-
stituents, the water-soluble components of the large-aggre-
gate fraction obtained during the lipid extraction procedure
was tested for its effectiveness in inhibiting a functionally
active surfactant.18 In brief, the watery upper phase of the
lipid extraction was collected, its protein content was deter-
mined (Biorad, Munich, Germany), and it was then lyo-
philized in a centrifuge under reduced pressure (Vacuum con-
centrator, Bachhofen, Munich, Germany). The lyophilized
proteins were reconstituted in bubble buffer in such a way
that the final protein concentration was 2 mg/mL after being
mixed with a natural bovine surfactant (phospholipid concen-
tration of 0.25/mL). For purposes of comparison, the natural
surfactant was also analyzed in the absence of protein and
with serum at various concentrations. The mixtures were
spun in a vortex and measured in the bubble surfactometer as
described earlier.
Statistical analysis. With time after CPB and clinical
recovery, the number of infants remaining intubated steadily
decreased. In addition, sufficient sample was not available
from all infants at all time points, and we set priorities regard-
ing which variables should be investigated first. We first deter-
mined the phospholipid content and the surface activity of a
sample. Because of the relatively low content of phospho-
lipids, especially in the small-aggregate fraction, this fraction
was sometimes used up completely, even without obtaining
sufficient material for analysis. The number of independent
data points from different individuals, determined in dupli-
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Fig 1. Time course of the oxygenation index of the infants
treated with CPB. For comparison, values from a control
group of infants without lung disease are given. The data
from infants 8 and 14, who had a nosocomial infection, were
not included. Data are means ± SEM of n different subjects
at each time point. *Indicates a difference from the control
group (on day 0, P = .043; day 1, P = .023; day 2, P = .009;
and day 3, P = .021).
Fig 2. Total protein in the large-aggregate fraction (LA) (A)
and small-aggregate fraction (SA) (B) of the lavage. C, Ratio
of protein in small- and large-aggregate (SA/LA) fractions.
Comparisons with the control group were made by t test. A,
On day 0, P = .028; day 1, P = .002. B, On day 0, P = .033;
day 1, P = .004; day 2, P = .001. C, On day 0, P = .032; day
1, P = .004; day 2, P = .008. Data are means ± SEM of n dif-




cate, are therefore indicated in the figures at each time point
and for each variable separately. All data are means ± standard
error of the mean (SE) for n independent determinations. To
calculate the standard deviation of the data, multiply SE by
√n.19 Spearman rank correlation coefficients were calculated
at each time interval and also for pooled data to estimate cor-
relations between oxygenation index, surface activity, and the
biochemical variables. Comparisons were made by the t test.
Exact P values are given where indicated. In all other cases, P
was > 0.1. Graph Pad Prism software (San Diego, Calif) was
used for data analysis.19
Results 
For the first few days after the operation the oxygena-
tion index was elevated above the level of the control
infants (Fig 1). In 2 infants (infants 8 and 14, Table I)
the respiratory support necessary increased with time,
their clinical status deteriorated, and the markers of
inflammation increased. Both infants responded to a
change in the antibiotic regimen, but only in 1 was an
infectious agent identified (positive blood culture on
day 3 with Enterobacter cloacae). These infants with
suspected nosocomial infection were excluded from the
analyses presented. In all the other infants the prolonged
intubation was due to pulmonary dysfunction and was
not related to hemodynamic problems, infections, or
other issues. This clear clinical impression is supported
by the data that the time to removal of the endotracheal
tube increased in proportion with the duration of CPB
(P = .0005, r = 0.717) (Table I). A longer CPB period
had resulted in more severe lung injury.
Total protein in lavages immediately after CPB was
increased 4 to 20 times above the levels of the control
infants (protein in large surfactant aggregate, 18.6 ± 4.7
m g/mL; in small surfactant aggregates, 52.9 ± 20.8





Fig 3. Surfactant protein A (SP-A) (A and B) and surfactant protein B (SP-B) (C and D) in the large-aggregate
fraction (LA) (upper panels) and small-aggregate fraction (SA) (lower panels) of the lavage. Comparisons with
the control group were made by t test. A, On day 0, P = .045; day 1, P = .024. B, On day 0, P = .045; C, On day 0,
P = .045; day 1, P = .024. D, On day 0, P = .028. Data are means ± SEM of n different subjects at each time point.
m g/mL) (Fig 2, A and B). The increase was pronounced
particularly in the small-aggregate fraction (Fig 2, C).
The surfactant associated proteins A and B followed a
similar course: on day 0 or day 1, they were increased
several times above the levels of the controls (surfac-
tant protein A in large surfactant aggregates, 1.0 ± 0.3
m g/mL, and in small surfactant aggregates, 2.5 ± 0.2
m g/mL; surfactant protein B in large surfactant aggre-
gates, 0.6 ± 0.1 m g/mL, and in small surfactant aggre-
gates, 0.3 ± 0.06 m g/mL) (Fig 3). As mentioned in the
“Methods” section, especially for these two variables
in the small-aggregate fraction, only a limited number
of samples was available.
The phospholipid content of the large-aggregate frac-
tion was about 4 times greater than that of the small-
aggregate fraction. Only on the day of CPB was a sig-
nificantly increased phospholipid content above the
level of the control infants observed (phospholipids
[expressed as micrograms of phosphate] in large sur-
factant aggregates, 12.5 ± 6.4 m g/mL, and in small sur-
factant aggregates, 1.4 ± 0.4 m g/mL) (Fig 4, A and B).
In contrast to total protein, the ratio of small to large
surfactant aggregates was not altered (Fig 4, C). On day
1 after CPB the phospholipid composition of the large-
aggregate fraction was still very characteristic for pul-
monary surfactant and differed only slightly from that
of the control infants (Table II).
Minimal surface tension, as a measure of the surface
activity, of the native large-aggregate fraction was
higher than in control infants from day 1 to day 3 (Fig
5, A). This was not the case with the lipid extract (Fig
5, B). These data suggested an inhibitory role of the
proteinaceous water-soluble fraction of native large
surfactant aggregates after CPB. Indeed, such an activ-
ity was demonstrated (Fig 6). However, on an equal
weight basis, we did not find any difference between
the effect of the proteinaceous fraction isolated from
control infants and that from infants after CPB. Thus
there was no evidence for specific and more potent
The Journal of Thoracic and
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Fig 4. Phospholipids in the large-aggregate fraction (LA) (A)
and small-aggregate fraction (SA) (B) of the lavage. C, Ratio
of phospholipids in small- and large-aggregate (SA/LA) frac-
tions. Comparisons with the control group were made by t
test. A, On day 0, P = .048. B, On day 0, P = .035. Data are
means ± SEM of n different subjects at each time point.
Table II. Phospholipid composition of the large-
aggregate fraction of small-volume lavages from
control infants and from infants 1 day after CPB
Control Infants 1 day 
Phospholipid class infants after CPB 
(% of total phospholipids) (n = 8) (n = 5) P value
Lysophosphatidylcholine 0.2 ± 0.1 0.6 ± 0.2 .123
Sphingomyelin 0.8 ± 0.5 1.5 ± 0.2 .246
Phosphatidylcholine 79.7 ± 1.4 72.4 ± 1.1 .004
Phosphatidylinositol 4.8 ± 0.7 6.1 ± 1.2 .362
Phosphatidyserine 1.8 ± 0.3 2.9 ± 0.2 .043
Phosphatidylethanolamine 2.7 ± 0.7 5.3 ± 0.8 .035
Phosphatidylglycerol 10.0 ± 3.1 7.7 ± 1.3 .592
Phosphatidic acid 2.1 ± 0.5 2.3 ± 0.4 .756
Cardiolipin 0.8 ± 0.3 0.5 ± 0.1 .539
Mean ± SEM, unpaired, 2-sided t test.
inhibitors present in the CPB sample only (Fig 6). Even
so, the total protein concentration has to be considered
in the infants with CPB that was increased several-fold
above control levels on the first few postoperative days.
No differences in the rate of adsorption between con-
trol infants and infants after CPB were observed (Fig 5,
B and D). Multiple regression analysis among the vari-
ables investigated (oxygenation index, protein, phos-




The presence of severe biochemical and functional
abnormalities of pulmonary surfactant and the recent
success of exogenous natural surfactant substitution
suggest an important role of impaired surfactant in
acute lung injury and acute respiratory distress syn-
drome.10-13 However, little is known about surfactant
after CPB, especially in young infants in whom acute
lung injury is more likely to develop. In this setting of
a rather homogeneous population and with infants of a
relatively low body weight, the administration of suffi-
cient amounts (eg, 200-500 mg/kg body weight) of sur-
factant appears feasible. However, to our knowledge no
data on the pulmonary surfactant activity are as yet
available in this group of infants.
In our serial analysis of the small-volume lavages, we
found reduced surface activity of the large-aggregate
surfactant fraction from postoperative day 1 to day 3.
This was concurrent with an increase of the oxygena-
tion index, although no correlations between these two
variables were found in the individual data sets.
Previously, it was shown that surfactant extracted from
lungs of patients after CPB at autopsy also had a
reduced capacity to lower surface tension in vitro.20
Others have demonstrated biochemical abnormalities





Fig 5. Surface tension of the large-aggregate fraction (LA) in the native state (A and C) and of its lipid extract (B and
D). Minimal surface tension of the pulsating bubble (g
min) (A and B) and of the static bubble after adsorption (g ads) (C
and D). *Indicates a difference from the control group, assessed by t test. A, On day 1, P = .005; day 2, P = .001; day
3, P = .001. Data are means ± SEM of n different subjects at each time point.
D
of surfactant, for example, quantitative alterations of
individual phospholipid species 24 hours and 8 days
after CPB in adults.21 In older children the ratio of phos-
phatidylcholine in small and large surfactant aggregates
was found to be increased 1 hour after CPB.22
Several lines of evidence support the view that the
impaired surface activity observed was mainly due to
the inhibition of surfactant function by edema fluid,
and not due to compositional deficiencies. First, the
surface activity of the lipid-extracted large surfactant
aggregate, for example, after removal of the nonlipid
components, was the same in controls and in infants
after CPB, and there were no differences after CPB
(Fig 5, B). Second, the proteins isolated from the large-
aggregate fraction were strongly inhibitory (Fig 6), and
they were increased several-fold on the first few days
after CPB (Fig 2). The concomitant increases in sur-
factant proteins A and B and phospholipids (Figs 3 and
4) are likely to have compensated a more severe deteri-
oration of surface activity of the native large-aggregate
fraction. Last, the phospholipid composition of the sur-
factant isolated from day 1 after CPB was characteris-
tic of normal surfactant18 and appeared not sufficiently
different from that of control infants to explain such
differences in surface activity (Table II). On the other
hand, we cannot completely rule out the possibility of
other functional alterations of the surfactant compo-
nents, for example, from proteolytic alterations of the
surfactant-specific proteins, that might not be
detectable in our ELISA-type assays. 
The general increase of surfactant components (eg,
total phospholipids and surfactant proteins A and B) we
found on the day of CPB may be due to a massive
secretory release of surfactant from intracellular stores
after reexpansion of the lungs after CPB that was not
counterbalanced by re-uptake.23,24 Although this notion
is supported by the minor changes of the phospholipid
pattern on day 1 after CPB and by a constant ratio of
phospholipids in small and large surfactant aggregates,
it remains speculative unless surfactant fluxes are mea-
sured in these infants.
A limitation of our study results from the inability to
obtain adequate samples on all patients owing to the
small sample size and low lavage volume. This result-
ed in relatively incomplete data on the proteins in the
small-aggregate fraction. Additionally, the fact that the
patients gradually dropped out of the study as they
became extubated may have biased the data, especially
at later time points. Because of this and because no lon-
gitudinal data analysis was performed, no conclusions
related to the pattern of changes across time can be
made. Thus mainly data from the first few postopera-
tive days can safely be compared with those of the con-
trol infants. 
Our study was performed in relatively sick infants
undergoing CPB of much longer duration than in earli-
er studies and thus having a substantial risk of postop-
erative severe lung injury. This was associated with sig-
nificant functional disturbances of the pulmonary
surfactant activity, indicating a possible role for surfac-
tant therapy. The surfactant preparation to be used
should have a high resistance to inhibition by proteina-
ceous edema fluid.8,25 Thus only preparations contain-
ing the surfactant proteins or their analogs are likely to
be successful. This is in line with previous experience
in adult patients, in whom the administration of a rela-
tively small dose (about 45 mg/kg body weight) of a
pure phospholipid mixture, did not improve lung func-
tion after CPB,26 whereas nebulized exogenous natural
surfactant (30 mg/kg body weight) appeared to be
promising.27
Before surfactant therapy after CPB can be safely
used in these infants, further systematic studies are
needed to define the optimal time point, the type of the
surfactant preparation, and the dose to be administered.
Only surfactant substitution on a rational data basis
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Fig 6. Inhibition of surfactant function by lavage constituents
and serum. A natural bovine surfactant (phospholipid con-
centration 0.25 mg/mL) was mixed with the proteinaceous
extract isolated from the large-aggregate fraction (LA) of the
lavages of the control infants (filled triangles, n = 4) and of
infants 2 to 4 days after CPB (filled squares, n = 11) at a pro-
tein concentration of 4 mg/mL. There were no differences
between the 2 groups. For comparison, surfactant alone
reduced surface tension to low values (open triangles, n = 7).
In the presence of normal human serum (protein concentra-
tion 4 mg/mL), the surface activity of the natural bovine sur-
factant was similarly inhibited as in the presence of the mate-
rial isolated from the lavages (open circles, n = 7). 
might be helpful in reducing postoperative morbidity
and mortality in these infants and thus needs to be
investigated systematically.
The infants with cardiac diseases were operated on at the
Department of Cardiac Surgery (B. Reichard), Klinikum
Grosshadern, University of Munich, Marchionini Strasse,
81377 Munich, Germany. Perioperative care was delivered at
the pediatric cardiology intensive care unit (H. Netz) of the
Kinderpoliklinik at the Klinikum Grosshadern, University of
Munich, Marchionini Strasse, 81377 Munich, Germany. We
thank all the nurses of the pediatric cardiology intensive care
unit staff for their continuous support and help with the col-
lection of small-volume lavages.
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